 In total, it is expected that a minimum of 70 and up to a maximum of 93 patients will be enrolled into the trial, the final number will depend on the number of dose escalations required to reach DLT. If 48 patients are enrolled in Part A, investigators will be permitted to enrol 45 patients in Part B, providing the maximum number of patients remains 93 patients across the study. 